tbuckley/cabot-search huggingface dataset:
Abstract P1-11-21: Effectiveness Analysis of Neoadjuvant Treatment by Using 4FE100C vs 6FE100C in Patients with Advanced Breast Cancer
Authors: N Ramirez-Torres, A Perez-Puentes, H Astudillo-de la Vega
Journal: Cancer Research (2010)

Abstract Objective: To detect the difference in the effectiveness of 6 FE100C as neoadjuvant chemotherapy (NCT) vs 4 FE100C and set the duration. Method. Forty-eight consecutive cases per group from January 2003 to December 2007 were registered. Patients received cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2 and 5-fluorouracil 500 mg/m2 (FE100C) with 4 or 6 cycles every 21 days. They were followed by surgery and radiotherapy. Results In the analysis, the number of the largest cycle was a predictor in clinical response. Theobjective complete clinical and partial response (cCR+cPR) was 62.5% and 87.5% with 4 FE100C and 6 FE100C respectively (p &amp;lt;0.003); the clinical benefit was better with six FE100C with a complete response rate (cCR) of 35.4% (CI 95%: 22% −48%, n=17). The distribution of best complete pathologic response (CPR) for 6 FE100C was significantly better than for 4 FE100C (20.8% vs.12.5%, p = 0.044). The most clinically important difference in gastrointestinal toxicity caused by 6 FE100C was the effect of mild to moderate vomiting (52.4% vs. 39% for 4 FE100C, p = 0.001); the severe leukopenia (2.43% vs. 1.56%, p= 0.401) and moderate anemia (2.08% vs. 0.52%, p = 0.142) for 6 FE100C and 4 FE100C respectively. There was no significant difference between regimens. The toxicity of the nausea, alopecia and hematologic toxicity in the effect of peripheral leukocyte count and platelet presented no significant difference between regimens. The moderate anemia was rescued with blood transfusion and severe leukopenia with filgastrim. There was no cardio toxicity, thrombocytopenia or other serious events. Conclusion: Both regimens were similar for the incidence of gastric toxicity and hematologic toxicity. The scheme of six FE100C was well tolerated in patients with LABC. It was confirmed a significant improvement in the pCR and cCR with intensified epirubicin dose (100mg/m2) for 6 cycles without granulocyte colony-stimulating factor. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-11-21.
PROPENSITY-SCORE COMPARISON OF PATIENTS WITH STABLE CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION BY RADIAL VERSUS FEMORAL APPROACH
Authors: Daniel Diehl, Jose de Ribamar Costa, Ricardo Costa, Bruno Gallindo de Mello, Daniel Chamié, Tannas Jatene, Dimytri Siqueira, Rodolfo Staico, Fausto Feres, Amanda Sousa, Alexandre Abizaid
Journal: Journal of the American College of Cardiology (2016)
Successful treatment of Cronkhite–Canada syndrome using anti-tumor necrosis factor antibody therapy
Authors: Daisuke Watanabe, Makoto Ooi, Namiko Hoshi, Michitaka Kohashi, Tomoo Yoshie, Nobunao Ikehara, Masaru Yoshida, Emmy Yanagita, Takashi Yamasaki, Tomoo Itoh, Takeshi Azuma
Journal: Endoscopy (2014)

Cronkhite–Canada syndrome (CCS) is a rare nonhereditary syndrome characterized by gastrointestinal polyposis and ectodermal changes [1]. Although several treatments, such as steroids, are available, the prognosis is poor, with a 5-year mortality rate of 55 % [2].
Mucosa-Associated Lymphoid Tissue Lymphoma of the Lung Detected with Ga-67 SPECT Imaging
Authors: SHUNG-SHUNG SUN, FENG-JU CHUANG, CHIA-HUNG KAO
Journal: Clinical Nuclear Medicine (2002)

From the Department of Nuclear Medicine, China Medical College Hospital, Taichung, Taiwan Received for publication October 29, 2001. Accepted January 18, 2002. Reprint requests: Chia-Hung Kao, Department of Nuclear Medicine, China Medical College Hospital, No 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail: [email protected]
TCT-649 Outcomes After Repeat Intervention With Everolimus-eluting Stent For Sirolimus-eluting Stent Restenosis Lesion With Stent Fracture
Authors: Yasunari Sakamoto, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano, Masahiro Yamawaki, Motoharu Araki
Journal: Journal of the American College of Cardiology (2014)
Safety and efficacy of a novel balloon colonoscope: a prospective cohort study
Authors: Ian Gralnek, Alain Suissa, Sveta Domanov
Journal: Endoscopy (2014)

<b>Background and study aims:</b> Although colonoscopy is the gold standard for detecting colorectal cancer (CRC), adenomas and cancers are missed. We aimed to establish the safety and feasibility of use of a novel balloon-colonoscope. <b>Patients and methods:</b> Patients (40 – 75 years) referred for CRC screening, polyp surveillance, or diagnostic evaluation were enrolled in a prospective pilot cohort study whose primary endpoint was device safety. Additional endpoints included success of and time to cecal intubation, withdrawal and total procedure times, polyp detection rate (PDR), adenoma detection rate (ADR), and success of polypectomies. <b>Results:</b> Among 50 patients (mean age 59.0 years, 27 women [54 %]), three were excluded (inadequate colon preparation, technical problem, abdominal hernia) and 47 were analyzed. Two patients experienced minor adverse events (diarrhea, abdominal pain). Cecal intubation rate was 47 /47 (100 %). Mean times, to reach cecum, withdrawal, and total procedure, were 4.3, 7.4, and 16.5 minutes, respectively. We identified 44 polyps (all successfully removed) in 25 /47 patients (PDR 53.2 %), 35 polyps (79.5 %) were 1 – 5 mm, 4 (9.1 %) 6 – 9 mm, and 5 (11.4 %) ≥ 10 mm. Of 44 polyps, 36 (81.8 %) were "adenomas"; 21/47 patients had ≥ 1 adenoma (ADR 44.7 %). <b>Conclusions:</b> The NaviAid G-EYE balloon-colonoscope appears safe and feasible to use. Comparative human studies are underway. Clinicaltrials.gov identifier: NCT01749722
Immunoglobulins on the Surface of Neoplastic Lymphocytes
Authors: Alan C. Aisenberg, Kurt J. Bloch
Journal: New England Journal of Medicine (1972)

Abstract Peripheral lymphocytes from 25 patients with chronic lymphocytic leukemia (CLL) and three with chronic lymphosarcoma-cell leukemia, and lymph-node cells from three of four with lymphocytic lymphoma bore on their cell surface IgM, which was readily demonstrated with fluorescein-conjugated antiserums. The lymphosarcoma cell differed from the cell of CLL in possessing much more surface immunoglobulin. Light-chain analysis of the surface IgM showed that cells bore either kappa or lambda determinants, but not both, indicating the clonal nature of these neoplasms. The serum of four leukemic patients was also found to contain small amounts of IgM M-components. Since the B lymphocyte (bone-marrow-derived) of laboratory animals bears large amounts of surface immunoglobulin and the T lymphocyte (thymus processed) does not, the findings favor the B-cell origin of these leukemic cells. A less likely possibility is that the CLL lymphocyte is a derepressed T cell.
IMPROVING SUCCESS OF TRANSRADIAL INTERVENTIONS IN SMALL ARTERIES (IRIS): A RANDOMIZED STUDY USING “COMPRESSION OF THE ULNAR ARTERY TECHNIQUE” IN SMALL RADIAL ARTERIES TO IMPROVE PROCEDURAL OUTCOMES
Authors: Sanjay Chugh, Yashasvi Chugh, Sunita Chugh, Satyajit Bose
Journal: Journal of the American College of Cardiology (2016)
P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.
Authors: PD Ryan, P Neven, KL Blackwell, LY Dirix, CH Barrios, WH Miller, LE Fein, D Fenton, RJ Benner, SJ Meech, L Paccagnella, B Sleight, D Yee, PE Goss
Journal: Cancer Research (2011)

Abstract Background Figitumumab (CP-751,871) is a fully human IgG2 monoclonal antibody that inhibits IGF-1R. Exemestane profoundly reduces estrogen production and has activity as first-line treatment in postmenopausal metastatic hormone receptor-positive (HR+) breast cancer (BC). Preclinical studies suggest cross-talk between the IGF-1R and estrogen receptor pathways. Combining agents that inhibit these pathways could benefit women with advanced BC. Methods This was an open-label, multicenter, randomized, phase II trial of first-line figitumumab + exemestane (Arm A) vs. exemestane alone (Arm B) in HR+ postmenopausal advanced BC. Eligibility included: age &amp;gt;18 yrs with Stage IIIB or IV disease; baseline ECOG PS ≤2. A high rate of grade [G] 3 and 4 hyperglycemia after figitumumab treatment prompted a protocol amendment in February 2010 requiring patients (pts) to have a baseline HbA1c &amp;lt;5.7%. Patients received exemestane 25 mg po daily ± intravenous figitumumab 20 mg/kg every 21 days. The primary endpoint was progression-free survival (PFS) in pts with baseline HbA1c &amp;lt;5.7%. Secondary endpoints included clinical benefit rate (CBR) and safety. Results Between 2007 and February 2011, 103 pts were randomized to Arm A and 102 to Arm B. Of these, 37 pts in Arm A and 40 pts in Arm B had baseline HbA1c &amp;lt;5.7%. These data are from an unplanned interim analysis which preceded premature study termination by the Sponsor for clinical development reasons and to expedite availability of data collected to date. Baseline demographics were balanced between arms. PFS, CBR and safety are summarized in Table 1. The majority of AEs were G1/2. In the Arm A overall population, the most common G3/4 events (in decreasing frequency) were hyperglycemia, diabetes mellitus, weight loss, isolated GGT elevation and fatigue. Hyperglycemia was uncommon in Arm B and in all pts with HbA1c &amp;lt;5.7%.[Table 2]. Conclusions The addition of figitumumab to exemestane was tolerable but overall did not improve PFS compared with exemestane alone in pts eligible for this trial. However, a trend toward benefit with figitumumab combined with exemestane in pts without evidence of baseline metabolic syndrome (HbA1c &amp;lt;5.7%) was observed together with improved tolerability; further study with this combination may be warranted. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-17-01.
Hematologic Complications Arising during Ristocetin Therapy
Authors: Eugene J. Gangarosa, Nathaniel S. Landerman, Paul J. Rosch, E. G. Herndon
Journal: New England Journal of Medicine (1958)

RISTOCETIN¶ is a new antimicrobial agent, a lyophilized preparation representing two antibiotics, ristocetin A and ristocetin B. These components have been isolated from the fermentation broth of the actinomycete species Nocardia lurida.1 In vitro and animal studies indicated marked bactericidal activity against gram-positive bacteria and mycobacteria. Advantages ascribed to ristocetin include low toxicity, lack of development of resistant organisms and an absence of crossresistance with other antibiotics.2 , 3 In a preliminary clinical study Romansky et al.3 demonstrated the efficacy of the drug in 16 cases. Local phlebitis was the only complication, but the dose was generally lower than the doses . . .
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer
Authors: Carl Diedrich Schlenkhoff, Florian Gaertner, Markus Essler, Matthias Schmidt, Hojjat Ahmadzadehfar
Journal: Clinical Nuclear Medicine (2016)

A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.
Diagnostic yield of a novel jumbo biopsy “unroofing” technique for tissue acquisition of gastric submucosal masses
Authors: S. Komanduri, L. Keefer, S. Jakate
Journal: Endoscopy (2011)

<b>Background and study aims:</b> Adequate tissue acquisition for the diagnosis of gastric submucosal masses (GSMs) has been challen ging for gastroenterologists. The use of standard biopsy forceps generally recovers non-diagnostic overlying mucosa. Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) provides a significant improvement, but is often still inadequate for diagnosis. The aim of the current study was to assess the efficacy of a novel jumbo biopsy unroofing technique (JUT) for tissue acquisition in GSM. <b>Patients and methods:</b> This prospective study recruited patients who were referred for EUS for the evaluation of GSM between 2006 and 2009. All patients underwent EUS with FNA when feasible followed by JUT. The primary outcome was diagnostic yield of JUT. <b>Results:</b> A total of 93 patients were enrolled, 72 of whom were included in the investigation; 16 patients were excluded with no evidence of a submucosal mass or extrinsic compression, and five patients were further excluded by pathology confirming mucosal lesions. Of the 72 jumbo biopsies 66 (92%) provided diagnostic tissue without significant complications and 42 (58%) had lesions amenable to FNA. Although 34 of the 42 lesions were deemed adequate at the time of on-site cytological evaluation, only 28 (67%) provided sufficient tissue for final diagnosis. More importantly, only 37/72 (52%) of all patients had lesions that required any further intervention. <b>Conclusions:</b> Utilization of JUT is safe and effective for diagnosis of GSM. The data suggest that the jumbo biopsy unroofing technique should be considered as an initial diagnostic strategy for GSMs found during upper endoscopy.
Rim Sign:
Authors: AARON K. HAYASHI, GABRIEL SOUDRY, PABLO E. DIBOS
Journal: Clinical Nuclear Medicine (1997)

A 62-year-old man had right upper quadrant abdominal pain, jaundice, fever, and leukocytosis. Tc-99m HIDA imaging showed nonvisualization of the gallbladder and increased pericholecystic hepatic uptake. The latter scintigraphic finding, known as a "rim sign," is often associated with acute gangrenous cholecystitis. Surgery in this patient showed acute cholecystitis with focal areas of gangrenous necrosis associated with a solitary calculus.
EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION
Authors: Ziad Hijazi, Jonas Oldgren, Johan Lindback, John Alexander, Stuart Connolly, John Eikelboom, Michael Ezekowitz, Christopher Granger, Elaine Hylek, Renato Lopes, Agneta Siegbahn, Salim Yusuf, Lars Wallentin
Journal: Journal of the American College of Cardiology (2016)
P444Therapeutic and prophylactic effects of oleuropein on ischemic and reperfusion injury of the heart in an in vivo and in vitro rat model
Authors: M Esmailidehaj, J Alihosaini, S Bajoovand, ME Rezvani
Journal: Cardiovascular Research (2014)

Purpose: Oleuropein is a very powerful phenolic antioxidant that exists in high concentrations in olive leaves. Several pharmacological benefits have been reported about oleuropein that nearly all of them linked to its antioxidant property. Given that oxidants play an important role in the incidence of ischemic cardiovascular diseases, in this study we wanted to evaluate the direct effects of oleuropein on the myocardial performance and incidence of arrhythmia in isolated and anesthetized rat heart models.

Methods: One hundred and twenty male Wistar rats were used to perform this study. To evaluate the direct effects of 10 and 100 μg/kg of oleuropein (perfusion of heart with solution containing oleuropein) on myocardial performance as a therapeutic and prophylaxis in isolated heart model, fifty rats were divided into five groups of eight in each. Also, to evaluate the direct effects of intravenous oleuropein (10 and 50 mg/kg in 1 ml normal saline) on the hemodynamic parameters and incidence of arrhythmia as a prophylaxis and therapeutic manner, fifty rats were divided into five groups of ten in each.Twenty male Wistar rats were divided into two groups of ten to evaluate the direct effects of lidocaine on the incidence of reperfusion arrhythmia in anesthetized rat as the positive control groups.

Results: The results showed that in isolated rat hearts, oleuropein in the manner of prophylaxis and therapeutic significantly decreased ischemia - reperfusion injuries that was evident with reduction of left ventricular end diastolic pressure and augmentation of contractility, coronary flow and ±dp/dt. In anesthetized rat hearts, intravenous administration of 10 mg/kg oleuropein had not significant effects on the mean arterial pressure and heart rate, but administration of 50 mg/kg oleuropein reduced the mean arterial pressure significantly without any effect on heart rate. Oleuropein in the manner of prophylaxis and therapeutic had a mild effect on the magnitude of reperfusion arrhythmia in anesthetized rat heart that was evident with increasing onset time of arrhythmias and reduction in the incidence of irreversible ventricular fibrillation. Antiarrhythmic effects of oleuropein were much weaker than the effects of lidocaine as an standard antiarrhythmic drug that was commonly used to treat the ventricular arrhythmia in clinic.

Conclusions: the results of this study shown that oleuropein has direct cardiotonic, vasodilator, anti-arrhythmic and hypotensive effects. Antiarrhythmic effect of oleuropein was much weaker than lidocaine as a standard antiarrhythmic drug in clinic.
Pelvic Exenteration for Carcinoma of the Cervix
Authors: Thomas F. Silva, Gilbert H. Friedell, Langdon Parsons
Journal: New England Journal of Medicine (1959)

DURING the past eighteen years there has been an increasing interest in radical surgery for cancer of the cervix. The rationale for the surgical approach is based on the observation that the natural history of neoplastic disease primary in the uterine cervix is one of local extension rather than distant spread to remote areas of the body. Autopsy studies of untreated patients dying of this disease indicate that the cancer is still confined to the pelvis in 56 per cent of the patients at the time of death.1 It is therefore logical to attack the problem of cancer localized to . . .
Psychiatric Complications of Open-Heart Surgery
Authors: Donald S. Kornfeld, Sheldon Zimberg, James R. Malm
Journal: New England Journal of Medicine (1965)

DURING the past ten years there have been reports of a significant incidence of psychiatric symptoms after cardiac surgery using closed-heart technics. The incidence of psychosis has clearly been greater than the 1:1500 reported by Knox1 in his study of a large group of general-surgery patients. These cardiac-surgery reports2 3 4 5 indicated an overall incidence of psychosis ranging from 1 to 19 per cent. A particularly high incidence of psychotic symptoms has now been noted during the recovery period after open-heart surgery at the Columbia–Presbyterian Medical Center.The aims of this study were as follows: to elucidate the nature and incidence of . . .
Testicular and Ovarian Resistance to Luteinizing Hormone Caused by Inactivating Mutations of the Luteinizing Hormone–Receptor Gene
Authors: Ana C. Latronico, James Anasti, Ivo J.P. Arnhold, Robert Rapaport, Berenice B. Mendonca, Walter Bloise, Margaret Castro, Constantine Tsigos, George P. Chrousos
Journal: New England Journal of Medicine (1996)

In normal males, luteinizing hormone (LH) regulates the function of Leydig cells and, hence, male sexual differentiation, pubertal androgenization, male sexual function, and fertility. Abnormalities in the function of Leydig cells result in primary hypogonadism and varying degrees of male pseudohermaphroditism.1-5 In these patients, Leydig cells are absent, hypoplastic, or unresponsive to stimulation with human chorionic gonadotropin (hCG), and studies of testicular-biopsy samples from some patients have revealed the absence of LH receptors.2,3 In normal women, LH stimulates the theca cells to produce androgen precursors for aromatization to estradiol by granulosa cells during the follicular phase of the menstrual cycle. . . .
Antineoplastic Dolastatins: Potent Inhibitors of Hematopoietic Progenitor Cells
Authors: S E Jacobsen, F W Ruscetti, D L Longo, J R Keller
Journal: JNCI Journal of the National Cancer Institute (1991)

Dolastatins 10 and 15, isolated from the shell-less marine mollusk Dolabella auricularia, are potent antineoplastic agents with unknown myelotoxic effects in vivo. The goal of this study was to determine whether the dolastatins inhibit the proliferation of normal hematopoietic progenitor cells. Assays to test inhibition of colony formation and of cell proliferation were performed in vitro with bone marrow cell preparations enriched for progenitor cells and with progenitor cell lines, respectively, using varying drug concentrations and exposure times. Dolastatins 10 and 15 both inhibited human and murine bone marrow cell colony formation in a concentration-dependent manner, with the concentration required for half maximal inhibition ranging from 0.1 to 1 pg/mL for dolastatin 10 and from 10 to 100 pg/mL for dolastatin 15. These concentrations are 25-fold to 100-fold lower than the concentration required for antineoplastic activity. Complete inhibition of human bone marrow cell colony formation was observed at concentrations of 10-100 pg/mL for dolastatin 10 and 1000-10,000 pg/mL for dolastatin 15. Committed progenitor cells and multipotential progenitor cells were similarly inhibited. The magnitude of inhibition of human hematopoietic cell colony formation was dependent on pre-exposure time to dolastatins 10 and 15, with a reversible effect up to 8 hours and with a 24-hour preincubation resulting in maximal (100%) and irreversible inhibition. Dolastatin 10 at a concentration of 10-100 pg/mL limited the proliferation of six human and four murine hematopoietic progenitor cell lines, as measured by tritiated thymidine incorporation, to between 34% and 83% of that occurring in the absence of the drug. These results indicate that the dolastatins are potent inhibitors of normal hematopoietic progenitor cell proliferation.
Trocar-assisted endoscopic retroperitoneal debridement. Non-NOTES salvage therapy for severe necrotizing pancreatitis
Authors: Martin Goetz, Jörg Glatzle, Thomas Kratt, Benjamin Wiesinger, Alfred Königsrainer, Nisar Malek
Journal: Endoscopy (2014)

A 68-year-old patient with severe biliary pancreatitis developed extensive retroperitoneal necroses, with air collections, extending from the pancreatic compartment to the pelvis ([Fig. 1 a, b]). Percutaneous and transgastric drainage (twice each) did not resolve the solid calcified infected material (vancomycin-resistant enterococci, Staphylococcus epidermidis, Neisseria subflava, Haemophilus influenzae, Candida albicans), which could not be adequately accessed transluminally [1]. Laparotomy was deemed too risky for this moribund patient (30-kg loss of body weight), who had persistent sepsis 9 weeks after presentation.